Director, AI Innovation & Partnerships

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified last checked Jun 13, 2026

Salary

Not verified not verified - source not recorded; timestamp not recorded

401(k) match

Listed Source: EMPLR_CONTRIB_INCOME_AMT. source Last checked Jun 13, 2026.

Was this benefit information wrong? Tell us.

Market context

Median wage (BLS OEWS)

$57,704 national median

Projected growth (BLS Employment Projections)

+0.9% - Slower

290% above the BLS national median for sales aggregate.

Matched to SOC 41-2031 - Sales aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, AI Innovation & Partnerships Seattle, WA, United States We are a fast-growing and dynamic organization seeking a DirectorAI Innovation & Partnerships to join our team. The Director AI Innovation & Partnerships builds and directs a portfolio of cross-functional AI use cases across the company, including discovery through clinical development, regulatory/QA, CMC, Commercial, and Corporate functions. The role translates scientific and business needs into technical capabilities and automated solutions. Position is responsible for developing and managing strategic external AI-focused partnerships to advance the company's programs and functions . Position reports to Associate VP of Structural Biology with dotted line reporting into CBDO and CEO. Good things are happening at Omeros! Who is Omeros? Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros' lead lectin pathway inhibitor YARTEMLEA ® , which inhibits the pathway's effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients ages two years and older, with a planned U.S. launch in January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review by the European Medicines Agency, with a decision expected in mid-2026. OMS1029, Omeros' long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical

Read the full description at effy.fa.us6.oraclecloud.com. FewerJobs shows a source-linked preview and links to the original posting.